345 related articles for article (PubMed ID: 24416732)
21. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
[TBL] [Abstract][Full Text] [Related]
23. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
Liu C; Lewis CM; Lou Y; Xu C; Peng W; Yang Y; Gelbard AH; Lizée G; Zhou D; Overwijk WW; Hwu P
J Immunother; 2012 Apr; 35(3):276-82. PubMed ID: 22421945
[TBL] [Abstract][Full Text] [Related]
24. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
Robak T; Robak E
BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
[TBL] [Abstract][Full Text] [Related]
25. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
26. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X; Chan HTC; Fisher H; Penfold CA; Kim J; Inzhelevskaya T; Mockridge CI; French RR; Duriez PJ; Douglas LR; English V; Verbeek JS; White AL; Tews I; Glennie MJ; Cragg MS
Cancer Cell; 2020 Jun; 37(6):850-866.e7. PubMed ID: 32442402
[TBL] [Abstract][Full Text] [Related]
27. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
Knorr DA; Dahan R; Ravetch JV
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11048-11053. PubMed ID: 30297432
[TBL] [Abstract][Full Text] [Related]
28. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
Kwekkeboom J; de Rijk D; Kasran A; Barcy S; de Groot C; de Boer M
Eur J Immunol; 1994 Mar; 24(3):508-17. PubMed ID: 7510232
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
30. Cell targeting and immunostimulatory properties of a novel Fcγ-receptor-independent agonistic anti-CD40 antibody in rhesus macaques.
Yan X; Ols S; Arcoverde Cerveira R; Lenart K; Hellgren F; Ye K; Cagigi A; Buggert M; Nimmerjahn F; Falkesgaard Højen J; Parera D; Pessara U; Fischer S; Loré K
Cell Mol Life Sci; 2023 Jun; 80(7):189. PubMed ID: 37353664
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.
van Hooren L; Georganaki M; Huang H; Mangsbo SM; Dimberg A
Oncotarget; 2016 Jul; 7(31):50277-50289. PubMed ID: 27385210
[TBL] [Abstract][Full Text] [Related]
32. B cell-B cell interaction through intercellular adhesion molecule-1 and lymphocyte functional antigen-1 regulates immunoglobulin E synthesis by B cells stimulated with interleukin-4 and anti-CD40 antibody.
Katada Y; Tanaka T; Ochi H; Aitani M; Yokota A; Kikutani H; Suemura M; Kishimoto T
Eur J Immunol; 1996 Jan; 26(1):192-200. PubMed ID: 8566066
[TBL] [Abstract][Full Text] [Related]
33. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
34. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Kornbluth RS; Stempniak M; Stone GW
Int Rev Immunol; 2012 Aug; 31(4):279-88. PubMed ID: 22804572
[TBL] [Abstract][Full Text] [Related]
35. Human T cell activation induced by a monoclonal mouse IgG3 anti-CD3 antibody (RIV9) requires binding of the Fc part of the antibody to the monocytic 72-kDa high-affinity Fc receptor (FcRI).
Ceuppens JL; Van Vaeck F
Cell Immunol; 1989 Jan; 118(1):136-46. PubMed ID: 2521302
[TBL] [Abstract][Full Text] [Related]
36. Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor.
Wheeler K; Pound JD; Gordon J; Jefferis R
Eur J Immunol; 1993 May; 23(5):1165-8. PubMed ID: 7682959
[TBL] [Abstract][Full Text] [Related]
37. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help.
Lederman S; Yellin MJ; Inghirami G; Lee JJ; Knowles DM; Chess L
J Immunol; 1992 Dec; 149(12):3817-26. PubMed ID: 1281189
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
Zhang X; Olsen HS; Chen S; So E; Zhou H; Burch E; Mérigeon EY; Block DS; Strome SE
J Immunol; 2016 Feb; 196(3):1165-76. PubMed ID: 26695368
[TBL] [Abstract][Full Text] [Related]
39. Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism.
Haagen IA; Geerars AJ; Clark MR; van de Winkel JG
J Immunol; 1995 Feb; 154(4):1852-60. PubMed ID: 7836769
[TBL] [Abstract][Full Text] [Related]
40. A new multivalent B cell activation model--anti-IgD bound to Fc gamma RI: properties and comparison with CD40L-mediated activation.
Cho S; Conrad DH
Int Immunol; 1997 Feb; 9(2):239-48. PubMed ID: 9040006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
